Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aurograb + vancomycin
- Development stage
- Phase 3
- Lead developer
- Neutec Pharmaceuticals
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Possibly Topical (experimental For Aurograb), Oral (rare, For Vancomycin In Specific Indications, But Not Combination Use)
01
Overview
Aurograb + vancomycin is a **combination antibacterial therapy** composed of two distinct agents: **aurograb**, an antibacterial protein derived from the bacteriophage-derived protein (specifically, the phage protein gp053), and **vancomycin**, a glycopeptide antibiotic. The combination is under investigation for its potential synergistic activity against **methicillin-resistant Staphylococcus aureus (MRSA)** and other Gram-positive infections. - **Aurograb** acts by binding to bacterial ribosomes, inhibiting protein synthesis and disrupting cell metabolism. Its interaction potentially sensitizes bacteria to other antibiotics[10]. - **Vancomycin** inhibits bacterial cell wall synthesis by binding firmly to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby blocking the peptidoglycan polymerization essential for bacterial viability[6]. This combination is primarily indicated in preclinical/experimental settings to overcome resistance mechanisms and enhance efficacy in difficult-to-treat MRSA or biofilm-related infections.
- Other names
- aurograb + vancomycin
02
Targets
D-Ala-D-Ala (D-Ala-D-Ala terminus)Neuraminidase
Beyond the preview
Go deeper on aurograb + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aurograb + vancomycin.